The search for molecular markers in AML that allow prediction of outcome has recently focused on genes involved in the regulation of programmed cell death (PCD). The aim of our study was to determine whether mRNA levels of Mdm-2, Bcl-2, Bclx L , Bad, and Bax are independent prognostic parameters for outcome. Transcript levels were analyzed by real-time quantitative RT-PCR in 232 samples collected either at diagnosis or following induction chemotherapy (ICT). Multivariate COX regression analysis adjusted for chemotherapy protocol, de novo vs secondary AML, and de novo vs relapsed AML indicated: (1) At diagnosis, high expression of Bad (P ‫؍‬ 0.015) and even more so high Bax and Bad levels (P ‫؍‬ 0.018) predicted adverse outcome, regardless of the response to ICT. In patients who subsequently failed to enter complete remission (CR), high levels of Bad, Bax and Bax high/Bad high were associated with an increased relative risk (RR) to die from tumor (RR ‫؍‬ 5.0 for Bad, 3.4 for Bax and 6.14 for Bax high/Bad high). (2) Following ICT, high expression of Bax (P ‫؍‬ 0.005) and high Bcl-2/Bax ratios (P ‫؍‬ 0.004) were independent predictors of unfavorable outcome, regardless of response to ICT. We conclude that high levels of Bax and Bad correlate with poor outcome, particularly in patients who do not enter CR and may serve as prognostic markers in AML.
Introduction
Inspite of considerable advances in combination chemotherapy, a significant number of malignant tumors become resistant to treatment. One major cause of either intrinsic or acquired resistance is the selective activation of a number of highly effective cellular defense mechanisms which have evolutionarily developed to protect the cell from exogenous toxic compounds. The first defense barrier to a great variety of cytotoxic drugs is formed by prominent members of the ATP-binding cassette membrane transporter family, such as Pglycoprotein and the multidrug resistance-associated protein (MRP) 1 which may lower intracellular drug concentrations to sublethal levels by active transport mechanisms. 2 Agents which escape the primary efflux mechanisms are generally believed to effect tumor cell killing by inducing apoptosis. 2 A second mechanism associated with primary resistance to chemotherapy-induced cell death may be the failure to activate the apoptotic machinery. Therefore, the search for new prognostic markers which may reflect tumor prognosis has recently focused on genes involved in the regulation of PCD. Experimental evidence has accumulated that PCD genes may be dysregulated in several types of human malignancies. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Particularly, members of the expanding Bcl-2 superfamily have been extensively studied. Current opinion holds that, if proapoptotic family members (eg Bax, Bad, Bak, Bid, Bcl-x S ) are in excess, cells execute a death command, but if antiapoptotic members (eg Bcl-2, Bcl-x L , Mcl-1) dominate, this program is inhibited. 17, 18 Death ligands such as Bad, represent an evolving set of proapoptotic molecules which appear to reside more proximal to Bcl-2 in the apoptotic pathway and connect upstream signal transduction paths with the Bcl-2 family thus modulating apoptosis. 18 There is evidence that Bax is transcriptionally activated by the tumor suppressor p53 and may be a key regulator of apoptosis.
18 p53 itself is controlled by murine double minute-2 (Mdm-2) which promotes inactivation of p53 by rapid degradation or by masking the p53 transactivation domain. 19, 20 We recently showed that low levels of Mdm-2 mRNA are associated with poor prognosis in soft tissue sarcoma. 21 Several attempts have been made to correlate expression levels of resistance genes with clinical outcome of leukemia. 14, [22] [23] [24] [25] Only a few studies have assessed the association between candidate gene expression and survival in acute myelogenous leukemia (AML), most of them with rather small patient numbers, and sometimes with conflicting results. 9, 22, 26, 27 Therefore, the potential prognostic value of apoptosis-related genes in AML remains to be elucidated. In this retrospective analysis, we used a semi-automated highthroughput methodology to study the expression of apoptosisrelated genes (Mdm-2, Bcl-2, Bcl-x L , Bad, Bax) in 232 AML specimens and correlated expression with response to ICT and survival.
Materials and methods

Patients, samples, and treatment
Two-hundred and thirty-two peripheral blood or bone marrow (BM) aspirates were collected from adult AML patients at diagnosis or after treatment with the first or second ICT cycle (71% paired samples) according to either the low-dose (AML'93) or the intermediate-dose (AML'96) protocols of the East-German Hematology and Oncology Study Group (OSHO) ( Complete remission was defined as р5% marrow blasts by morphology. All other patients were classified as nonresponders (NR). At diagnosis, the mean percentage of blasts in samples were 65 ± 22% (median: 70%). After ICT, the NR group showed 46 ± 31% blasts (median: 48%) and the CR group 4 (1% blasts (median: 4%). Patients with acute promyelocytic leukemia (FAB-M3) and patients who died from toxicity were excluded from the analysis.
FACS analysis
CD34
+ cells were counted with a FACscan flow cytometer following incubation with the phycoerythrin-labeled HPCA-2 monoclonal antibody (Becton Dickinson, San Jose, CA, USA).
Clinical sample preparation
Mononuclear cells from 5-10 ml blood (9% of samples) or BM samples (91% of samples) were collected after separation on sterile Histopaque-1077 lymphocyte separation medium (Sigma, St Louis, MO, USA), washed three times with phosphate-buffered saline, and homogenized with 2 ml of RNAzol 'B' (Tel-Test, Friendswood, TX, USA) or 1 ml of Reagent 14 (Integrated Separation Systems, Natick, MA, USA). Homogenates were stored at −20°C until RNA preparation was performed.
RNA isolation and reverse transcription (RT)
Total RNA was isolated manually or in an Autogen 540 nucleic acid extraction robot (Integrated Separation Systems). cDNA was synthesized from 1 g aliquots in a 20-l standard 
High-throughput transcript analysis by quantitative real-time fluorescence PCR
Mdm-2 (splice variants A, B, C, D; not E), Bcl-2, Bcl-x L , Bax (splice variants alpha, beta, delta, sigma, zeta; not gamma and epsilon), Bad, and glyceraldehyde-3-phosphate dehydrogenase GAPDH) transcripts were measured from cDNA in duplicate experiments by ready-to-use PCR testkits (Roboscreen Gesellschaft fü r molekulare Biotechnologie, Leipzig, Germany). Briefly, conventional 96-well bases were loaded with one eight-well ready-to-use reference-DNA strip which was storage-stable coated with eight different amounts of respective reference-DNA for quantitation of the desired transcripts, forward and reverse primer, and the TaqMan probe. The probes were either 5Ј-labeled with the fluorescent reporter dye 6-carboxyfluorescein (FAM) or 2,7-dimethoxy-4,5-dichloro-6-carboxyfluorescein (JOE) for GAPDH, and the common 3Ј-fluorescent quencher dye 6-carboxytetramethylrhodamine (TAMRA) in order to generate the respective standard reference curves for each run. The remaining free positions were loaded with the required number of sample tubes containing only the respective TaqMan oligonucleotide sets. Reaction premixes containing PCR buffer, the passive fluorescence dye 6-carboxy-tetramethyl-rhodamin (ROX), dNTPs, and 0.5-1 U of AmpliTaq 'GOLD' (Applied Leukemia   Table 2 Univariate analysis on prognostic factors in AML at diagnosis and following ICT
Prognostic factor
At diagnosis After ICT 
Statistical analyses
Statistics were performed using the SPSS 9.0 software program (SPSS, Chicago, IL, USA). Univariate survival analysis was per- Table 3 Medians and ranges of apoptosis-related transcripts Values calculated separately either at the time of initial diagnosis or following ICT. All data are expressed as zmol/amol GAPDH transcripts measured in the same cDNA sample.
Figure 1
Kaplan-Meier plots of Bax, Bad, and interacting Bax as well as Bad levels measured at diagnosis. High expression is defined as greater than the median, and low expression is defined as less than or equal to the median value. Statistical analysis performed by the log-rank test, corresponding P values indicated in the figure. Symbols: '+': censored data, P and RR values labeled by asterisk are obtained from multivariate Cox regression analysis, N, number of samples.
formed using the Kaplan-Meier method and log-rank test. A multivariate Cox regression model was used to estimate the influence of individual gene expression parameters on prognosis, adjusted for the covariates AML sub-type and chemotherapy protocol. Changes of likelihood interactions between Bax and Bad gene expression were analyzed using an interaction term. 28 High Bax and Bad were classified as '1', low Bax or Bad values as '0'. P values of less than 0.05 were considered statistically significant.
Results
Validation of quantitative RT-PCR
The expression of the Bcl-2 family genes Bcl-2, Bcl-x L , Bad, Bax, and the p53 antagonist Mdm-2 were assessed by recently developed ready-to-use fluorescence RT-PCR assays based on the TaqMan technology. The repeatability of the Roboscreen assays was good: the coefficients of variation of the mean reference curves slopes were usually below 5% which indicates reliable standard stability. 21, 29 The precision of the assays was tested by analysis of cDNAs prepared from the K562 and CCRF ADR5000 cell lines for Bcl-2 and GAPDH expression, respectively. Input analyte amounts at the attomole detection level, ie typical for GAPDH reference transcripts, were detected within a 10% precision rate, whereas Bcl-2 transcripts which are usually at a low zeptomole detection level were detected within a precision of ±28% (eight repeated analyses performed for each cell line, data not shown). All values were adjusted for the number of GAPDH transcripts, which have been reported to be constant in various tumors, tissues and cell lines.
30-32
Univariate and multivariate correlation between transcript levels and outcome at the time of diagnosis
The most important conventional prognostic parameters are shown in Table 2 . Univariate Kaplan-Meier regression analysis and log-rank test showed that poor prognosis was strongly associated with the low-dose therapy protocol compared to the intermediate-dose protocol (P = 0.014) and with later NR compared to CR (P = 0.004). A trend towards unfavorable prognosis was found for relapsed and secondary AML compared to de novo AML (P = 0.097) and for unfavorable karyotypes compared with standard or favorable karyotypes (P = 0.186) confirming earlier data from the literature. 33, 34 There To assess the influence of individual transcript amounts on prognosis, medians were calculated for each transcript separately at diagnosis and following ICT in order to group patients into high and low expressing individuals (Table 3) . For this analysis, AMLs at presentation and newly diagnosed relapsed leukemias were analyzed together. Patients were divided according to their expression level of the respective transcript into high (expression above median) and low (expression below or equal to median value) expressing groups, and survival was compared between the two groups. In univariate Kaplan-Meier analysis, the most important predictors of survival at diagnosis were Bad (P = 0.026) and the combination of high Bad and high Bax levels (P = 0.014), whereas Bax
Figure 2
Kaplan-Meier plots of Mdm-2, mdr-1, and Bax expression, and Bcl-2/Bax ratios after ICT treatment. High and low expression is defined as described previously. Statistical analysis is performed by the log-rank test (P), *data confirmed by multivariate Cox regression analysis. alone showed only a marginal impact on survival (P = 0.095) (Table 2, Figure 1 ). These univariate findings remained stable when Bad and Bax expression were analyzed by a multivariate COX model adjusted for (1) chemotherapy protocol (AML 93 vs AML 96), (2) de novo vs secondary AML, and (3) de novo vs relapsed AML (Table 4) . Cox analysis further revealed that Bad and combined Bax/Bad levels above the median values are independent negative prognostic parameters for survival (P = 0.015 and P = 0.018, respectively) at the time of initial diagnosis, whereas Bax alone remained borderline significant (P = 0.064) confirming the univariate analysis. Furthermore, the data indicate that AML patients characterized by Bad, Bax or Bax as well as Bad levels above median showed a 1.78-fold, 1.52-fold and 1.83-fold higher relative risk of tumor-related death compared to patients with levels equal to or below the median (Table 4, Figure 1 ). All other transcripts were without predictive value at diagnosis.
Univariate and multivariate correlation between transcript levels and outcome after ICT
After ICT (regardless of response), the initially observed correlation between survival and expression of Bad disappeared, whereas a poor prognosis was now associated with high Bax levels (P = 0.040) and high Bcl-2/Bax ratios (P = 0.044, Table  2 , Figure 2) . Analysis by the COX model showed that Bax expression above the median, high levels of Bax and Bad, and high Bcl-2/Bax ratios were independent prognostic factors of adverse outcome and correspond to a 2.40-fold, 2.80-fold and 2.62-fold RR, respectively, of tumor-related death (Table 4 , Figure 2 ). Mdm-2 mRNA levels had only borderline impact on survival after treatment (P = 0.098, Figure 2 ).
Since the response to ICT is an important prognostic factor in itself, the groups of complete responders and nonresponders were analyzed separately. Bax and Bad expression influenced survival only within the NR group. NR expressing high levels of Bax, Bad or high levels of Bax and Bad had a much worse prognosis than patients with low expression, both at diagnosis (P = 0.001, P = 0.01 and P = 0.002, respectively) and after ICT (P = 0.001, P = 0.045 and P = 0.004). The corresponding RR values are 4.97, 3.42 and 6.14 respectively, at the time of diagnosis and 9.62, 3.46 and 10.82, respectively, after ICT (Table 5, Figure 3 ). Except in one patient, failure to achieve CR together with high expression of Bax at diagnosis Table 5 Transcript amounts and ratios correlated with survival of patients divided into non-responders (NR) and complete responders (CR)
Transcript or ratio NR CR At diagnosis After ICT At diagnosis After ICT P R R P R R P R R P R R P and RR values obtained from multivariate Cox regression analysis correspond to either high expression levels or high transcript ratios compared with low expression levels or ratios, respectively. High levels were always associated with poor prognosis. Bcl-2, Bcl-x L and Mdm-2 data were always not significant. a Mean values obtained from the Cox analysis of each gene expression parameter assessed separately for its impact on prognosis.
predicted survival of less than 12 months, whereas none of the group characterized by high Bax and Bad levels survived the first 9 months after ICT start (Figure 3 ). In contrast, a similar tendency but no statistical significance was observed in patients who achieved CR (Figure 3) . Consequently, the strongest parameter for predicting poor prognosis in NR is the combination of increased Bax and Bad levels. In patients achieving CR Bad and Bax levels were not correlated with outcome. However, patients with high Bcl-2/Bax and Bcl-x L /Bad ratios after treatment were characterized by a 2.3-fold and 2.5-fold increased RR to die from their leukemia ( Table 5) .
Discussion
The aim of our study was to determine whether mRNA levels of the apoptosis-regulators Mdm-2, Bcl-2, Bcl-x L , Bad, and Bax could serve as independent parameters to predict clinical outcome in AML. The semi-automated high-throughput methodology used in our study allows for a much more rapid quantitation (up to 200 samples per day and method) of expression of apoptosis-related genes than would be possible by traditional techniques such as quantification at the protein level by Western blotting, 9, 35, 36 immunohistochemistry, 6, 8, 13, 15, 37 or flow cytometry. 36 We show that mRNA expression of several genes has a distinct prognostic value at the time of initial diagnosis (eg Bad, Bax) as well as after completing ICT (eg Bax, Bad, Bcl-2/Bax ratio, Mdm-2).
The clearest correlation exists between high expression of the proapoptotic genes Bad and Bax and poor prognosis. This is surprising since one might expect an inverse correlation, at least at the protein level. 25, 28, 37 Remarkably, the combination of high Bad and Bax values appear to be as strong predictive parameters as the conventional risk factors, relapse and treatment protocol, but with the considerable advantage of being prospectively available. Regarding Bax, similar observations were made in non-Hodgkin's lymphoma, 15 acute lymphoblastic leukemia (ALL), 38 breast, 13 pancreatic 4 and ovarian carcinomas. 8 Our findings are also consistent with the observation that patients with small-cell lung cancer and Baxpositive/Bcl-2-negative tumors have a poor prognosis, 7 and that higher ratios of Bcl-2/Bax correlate with failure to achieve CR in AML [39] [40] [41] or chronic lymphocytic leukemia (CLL). 24 In contrast, increased Bax protein expression was found to be
Figure 3
Bax, Bad and interacting Bax and Bad expression at diagnosis and response to treatment. Kaplan-Meier survival analysis and logrank test separately performed for NR and CR AML patients expressing high or low mRNA amounts of Bax, Bad, or high Bax and Bad compared with low Bax or Bad levels, respectively. *Data confirmed by multivariate Cox regression analysis. correlated with improved in vitro survival of CLL cells, 24 cervical, 12 pancreatic, 4 low-grade urinary bladder cancer, 11 esophageal squamous cell carcinoma 25 and hepatic metastases of colorectal cancer. 6 It should be stated here that in a significant number of studies only the Bax-alpha isoform was characterized, 3, 25, 42 whereas the assay used in this study detects the majority of human alternative spliced Bax mRNA isoforms (ie alpha, beta, delta, sigma, zeta) except gamma and epsilon. A recent study found no correlation to prognosis in AML at diagnosis. 41 Furthermore, an important observation is that the uniform NR group may be subdivided into a high and low risk subgroup based on Bax or Bad expression at diagnosis as well as after ICT. Surprisingly, this correlation was restricted to refractory patients. It is not clear why high Bax mRNA levels at diagnosis are not predictive of poor outcome if patients achieve a CR. One possible explanation is that if ICT fails to elimLeukemia inate the clone that expresses high levels of Bax and Bad, all subsequent attempts will also fail to achieve this. Alternatively, one could speculate that the physiological function of Bax in an AML cell prior to chemotherapy is different from its function after the cell has evolved under the selective pressure of cytotoxic agents. An explanation for the unexpected correlation between high Bax and Bad mRNA levels and poor prognosis may be that transcripts may not necessarily reflect protein levels. This is, however, somewhat unlikely because a significant number of studies that investigated protein levels yielded results very similar to ours. [7] [8] [9] 13, 15 On the other hand, overexpression of Bax may be the result of mutations in the DNA-binding motif of p53; such mutations have recently been demonstrated in non-small-cell lung cancer. 43 p53 mutations have also been reported in a significant proportion of AML 44 and we are currently investigating whether such mutations are correlated with high levels of Bax. Another possible expla-nation is loss-of-function mutations of Bax, which have been found in 21% of human hematopoetic cell lines, most commonly in ALL subset 45 and some gastrointestinal cancers. 46 These mutations may affect the capability of Bax to dimerize, 45 and may result in a compensatory increase of Bax expression. To our knowledge, no data with regard to Bax mutations in AML are available. Since Bax plays a role in the control of proliferation as well as apoptosis, 18 ,47 a third explanation for the relationship between Bax overexpression and poor prognosis could be that its major function has shifted towards enhancement of cell proliferation. 9, 18 Because Bad is able to displace Bax from Bcl-x L 48 its simultaneously highlevel expression may further enhance the putative proliferative effect of Bax.
Little is known from the literature that could explain the potential physiological role of increased Bad mRNA levels and their strong correlation with poor survival in AML. Interestingly, in CLL, higher levels of the anti-apoptotic proteins Mcl-1 and Bag-1, which are also death ligands, were strongly correlated with failure to achieve CR after chemotherapy. 14 The Bad protein has been shown to be rapidly inactivated by serine-phosphorylation on residues 112 and 136 followed by its sequestration in the cytosol by 14-3-3 proteins. 18 This inactivation can be induced by survival-promoting cytokines such as IL-3 which lead to the activation of kinases like Akt and Raf-1 that phosphorylate Bad. 18, 49 Interestingly, up to 90% of AML tumor cells appear to secrete IL-1␤, which can induce cells in the microenvironment to produce IL-3. 50 Therefore, up-regulation of proapoptotic Bad may be an attempt to compensate for increased post-translational inactivation of the protein. In line with this concept, a recent publication demonstrated that in 40 out of 41 AML samples the Bad protein was phosphorylated on both possible residues. 51 Whether this is the case in our samples is currently under investigation.
In summary, our data provide a rationale to use Bad and Bax transcript levels as independent predictive factors to assess prognosis in AML patients at diagnosis as well as after ICT. If confirmed in a prospective study, measurement of certain apoptosis-related genes could guide risk-adapted therapy to aid treatment stratification in the future.
